A new study has confirmed the potential of Chemomab’s CCL24-neutralizing antibody, CM-101, to treat primary sclerosing cholangitis (PSC), a rare fibrotic liver disease. The…
A new study has confirmed the potential of Chemomab’s CCL24-neutralizing antibody, CM-101, to treat primary sclerosing cholangitis (PSC), a rare fibrotic liver disease. The…
Login below or Register Now.
Already registered? Login.